- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06815471
CRF2 -agonist til behandling af forværring af hjertesvigt (CRAFT-WHF)
Corticotrophin frigørelsesfaktor 2 til behandling af forværring af hjertesvigt (WHF) - CHRAFT -WHF -undersøgelsen
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Corteria Chief Medical Officer
- Telefonnummer: 610-787-2998
- E-mail: francesca.lawson@corteriapharma.com
Undersøgelse Kontakt Backup
- Navn: Clinical Operations Director
- E-mail: Brian.Sontag@Corteriapharma.com
Studiesteder
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Aktiv, ikke rekrutterende
- Indiana University Health Methodist Hospital
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Aktiv, ikke rekrutterende
- Wayne State University - Detroit Receiving Hospital
-
Detroit, Michigan, Forenede Stater, 48235
- Aktiv, ikke rekrutterende
- Wayne State University - Sinai Grace Hospital
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27401
- Aktiv, ikke rekrutterende
- Cone Health Moses Cone Hospital
-
Raleigh, North Carolina, Forenede Stater, 27607
- Rekruttering
- NC Heart and Vascular Research, LLC
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73135
- Trukket tilbage
- South Oklahoma Heart Research, LLC
-
-
-
-
-
Tbilisi, Georgien, 0102
- Afsluttet
- Aleksandre Aladashvili Clinic LLC
-
Tbilisi, Georgien, 0112
- Afsluttet
- LTD "Israeli-Georgian Medical Research Clinic Healthycore"
-
Tbilisi, Georgien, 0159
- Afsluttet
- Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research
-
Tbilisi, Georgien, 0159
- Afsluttet
- Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials
-
Tbilisi, Georgien, 0159
- Afsluttet
- Bokhua Memorial Cardiovascular Center LTD
-
Tbilisi, Georgien, 0159
- Afsluttet
- St. Michael's Hospital LLC
-
Tbilisi, Georgien, 0159
- Afsluttet
- Tbilisi Heart and Vascular Clinic, LTD
-
Tbilisi, Georgien, 0167
- Afsluttet
- Georgian Dutch Hospital
-
Tbilisi, Georgien, 0186
- Afsluttet
- LTD Tbilisi Heart Center
-
-
-
-
-
Bialystok, Polen, 15-276
- Aktiv, ikke rekrutterende
- Klinika Kardiologii i Chorób Wewnętrznych z Oddziałem Intensywnego Nadzoru Kardiologicznego (OINK), Uniwersytecki Szpital Kliniczny w Białymstoku
-
Gdansk, Polen, 80-214
- Aktiv, ikke rekrutterende
- I Klinika Kardiologii, Uniwersyteckie Centrum Kliniczne
-
Krakow, Polen, 30-688
- Aktiv, ikke rekrutterende
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Kłodzko, Polen, 57-300
- Rekruttering
- Zespół Opieki Zdrowotnej w Klodzku, Oddzial Kardiologii
-
Lodz, Polen, 92-213
- Aktiv, ikke rekrutterende
- II Klinika Kardiologii, SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
-
Rzeszów, Polen, 35-301
- Trukket tilbage
- Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej w Rzeszowie
-
Torun, Polen, 87-100
- Aktiv, ikke rekrutterende
- Oddział Kliniczny Kardiologii i Intensywnej Terapii Kardiologicznej
-
Wroclaw, Polen, 50-556
- Rekruttering
- Instytut Chorób Serca, Zakład Badań Klinicznych Chorób Układu Krążenia, Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
-
-
-
-
-
Arad, Rumænien, 310037
- Rekruttering
- Emergency County Clinical Hospital Arad, Cardiology department
-
Bucharest, Rumænien, 20125
- Aktiv, ikke rekrutterende
- Spitalul Clinic Colentina
-
Bucharest, Rumænien, 022328
- Aktiv, ikke rekrutterende
- Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 1
-
Bucharest, Rumænien, 022328
- Aktiv, ikke rekrutterende
- Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 3
-
Craiova, Rumænien, 200642
- Rekruttering
- Craiova County Emergency Clinical Hospital
-
Timișoara, Rumænien, 300079
- Aktiv, ikke rekrutterende
- Spitalul Clinic Municipal de Urgenta Timisoara
-
-
-
-
-
Belgrade, Serbien, 11000
- Rekruttering
- University Clinical Center of Serbia, Clinic for Cardiology, Emergency Cardiology Department
-
Belgrade, Serbien, 11000
- Afsluttet
- Clinical Hospital Center "Dr Dragisa Misovic Dedinje"
-
Belgrade, Serbien, 11000
- Aktiv, ikke rekrutterende
- Institute for Cardiovascular Diseases Dedinje
-
Belgrade, Serbien, 11000
- Aktiv, ikke rekrutterende
- University Clinical Center of Serbia, Clinic for Cardiology, Department for the testing and treatment of congenital and acquired heart defects
-
Belgrade, Serbien, 11000
- Aktiv, ikke rekrutterende
- University Clinical Center of Serbia, Clinic for Cardiology, Heart Failure Ward
-
Kragujevac, Serbien, 34000
- Aktiv, ikke rekrutterende
- University Clinical Center Kragujevac, Clinic for Cardiology
-
Leskovac, Serbien, 16000
- Trukket tilbage
- General Hospital Leskovac, Cardiology Department
-
Niš, Serbien, 18000
- Rekruttering
- University Clinical Center Nis, Clinic for Cardiology
-
Niška Banja, Serbien, 18205
- Aktiv, ikke rekrutterende
- Institute For Treatment and Rehabilitation "Niska Banja"
-
-
-
-
-
Seville, Spanien, 41013
- Rekruttering
- Hospital Universitario Hospital Virgen del Rocío
-
Valencia, Spanien, 46026
- Rekruttering
- Hospital Universitari i Politecnic La Fe
-
Valencia, Spanien, 46014
- Aktiv, ikke rekrutterende
- Consorcio Hospital General Universitario de Valencia
-
-
Madrid
-
Fuencarral-El Pardo, Madrid, Spanien, 28034
- Aktiv, ikke rekrutterende
- Hospital Universitario Ramon y Cajal
-
Majadahonda, Madrid, Spanien, 28222
- Aktiv, ikke rekrutterende
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
Murcia
-
El Palmar, Murcia, Spanien, 30120
- Aktiv, ikke rekrutterende
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Valencia
-
Valencia, Valencia, Spanien, 46010
- Rekruttering
- Hospital Clínico Universitario de Valencia
-
-
-
-
-
Brno, Tjekkiet, 62500
- Rekruttering
- Fakultní nemocnice Brno
-
Krnov, Tjekkiet, 79401
- Aktiv, ikke rekrutterende
- Sdružené zdravotnické zařízení Krnov
-
Ostrava, Tjekkiet, 70852
- Rekruttering
- Fakultní nemocnice Ostrava
-
Slaný, Tjekkiet, 27401
- Rekruttering
- Nemocnice Slaný
-
-
-
-
-
Budapest, Ungarn, 1122
- Rekruttering
- Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika
-
Budapest, Ungarn, 1145
- Rekruttering
- Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály
-
Pécs, Ungarn, 7624
- Aktiv, ikke rekrutterende
- Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika
-
Szeged, Ungarn, 7625
- Aktiv, ikke rekrutterende
- Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet
-
Zalaegerszeg, Ungarn, 8900
- Rekruttering
- Zala Vármegyei Szent Rafael Kórház, Kardiológiai Osztály
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed written informed consent
- Previous diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
- Prescribed an oral loop diuretic for at least 1 month preceding the index event
- NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL
- Requires treatment with i.v. diuretics for volume overload
- At least 1 risk factor for diuretic resistance
- Admitted to the hospital not more than 120 hours prior to randomization
Exclusion Criteria:
- Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia)
- Administration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
- Requirement for, or planned use of LVADs, IABP, or any type of MCS
- History of solid organ transplant or active on a transplant list
- SBP <100 mmHg
- eGFR < 20 mL/min/1.73 m2
- CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study
- Severe stenotic cardiac valvular disease
- Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (> 2 L/min)
- Uncorrected severe hyperthyroidism or hypothyroidism
- Severe restrictive, obstructive, or infiltrative cardiomyopathy
- Body weight < 70 kg at screening
- Use of any investigational drug(s) within 5 half-lives of screening
- At high risk of death, defined as life expectancy ≤1 year (such as participants in potential impending cardiogenic shock), or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
- Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures
- Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
- Increased lactate levels > upper limit of normal (local laboratory) at screening
- Severe chronic liver disease (such as cirrhosis)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
28-day treatment |
|
Eksperimentel: COR-1167 lav dosis
|
28-day treatment |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Natriuresis
Tidsramme: 24 hours
|
Urinary sodium excretion |
24 hours
|
|
Body weight
Tidsramme: 7 days
|
Changes in body weight |
7 days
|
|
NT-proBNP
Tidsramme: 7 days
|
Changes in NT-proBNP |
7 days
|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)
Tidsramme: 28 days
|
Changes in KCCQ-TSS - The score ranges from 0 to 100 with higher score indicating a better health status |
28 days
|
|
Left Atrial Volume index (LAVi)
Tidsramme: 2 days
|
Changes in LAVi - LAV-i is an index of cardiac function measured by echocardiogram |
2 days
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studiestol: Jeffrey Testani, MD, Yale University
Publikationer og nyttige links
Generelle publikationer
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21;129(3):399-410. doi: 10.1161/01.cir.0000442015.53336.12. No abstract available.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. No abstract available.
- Rademaker MT, Charles CJ, Ellmers LJ, Lewis LK, Nicholls MG, Richards AM. Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension. 2011 Jun;57(6):1136-44. doi: 10.1161/HYPERTENSIONAHA.111.173203. Epub 2011 May 2.
- Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Circ Heart Fail. 2009 Nov;2(6):532-40. doi: 10.1161/CIRCHEARTFAILURE.109.861336. Epub 2009 Sep 22.
- Chan WY, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Fail. 2013 Oct;1(5):433-41. doi: 10.1016/j.jchf.2013.07.003. Epub 2013 Sep 11.
- Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Perez-Calvo JI, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018 May 1;258:185-191. doi: 10.1016/j.ijcard.2018.01.067.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- COR1167-201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
This is not a phase 3 trial that would benefit from IPD sharing
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .